Karyopharm Therapeutics Inc
(FRA:25K)
€
0.5734
-0.0194 (-3.27%)
Market Cap: 84.88 Mil
Enterprise Value: 143.15 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 64/100 Karyopharm Therapeutics Inc at RBC Global Healthcare Conference (Virtual) Transcript
May 19, 2020 / 12:35PM GMT
Release Date Price:
€16.1
(-9.04%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Good morning, everyone. I'm Brian Abrahams, senior biotech analyst at RBC Capital Markets. Thanks, again, for joining us. Our next featured company is Karyopharm, represented by their CEO, Michael Kauffman; their CFO, Mike Mason; as well as Ian Karp, their VP of Investor and Public Relations. Thanks very much, guys, for joining us.
Michael G. Kauffman
Karyopharm Therapeutics Inc. - Co-Founder, CEO & Director
Great to be here. Thanks, Brian.
Questions & Answers
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
So maybe just kicking off on the clinical side. We're going to be seeing some data upcoming from your positive Phase III BOSTON study at ASCO in just a few weeks. Can you tell us a little bit about what we should be looking for out of XPOVIO in this data? And what you think is going to be most useful for physicians to determine how to best use the agent, coming out
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot